Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Blood (2023) 142 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2023-182347

Published: 2023

Journal Articles

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2015) 126 (23): 2735.

https://doi.org/10.1182/blood.V126.23.2735.2735

Published: 2015

Journal Articles

Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenstrom's Macroglobulinemia

Blood (2014) 124 (21): 3072.

https://doi.org/10.1182/blood.V124.21.3072.3072

Published: 2014

Journal Articles

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Francesco Zaja, Stefano Volpetti, Annalisa Chiappella, MD, Flavia Salvi, MD, Angelo M. Carella, Adalberto Ibatici, Pier Paolo Piccaluga, Stefano A. Pileri, Davide Rossi, MD PhD, Pier Luigi Zinzani, Caterina Patti, Umberto Vitolo, Alfonso D'Arco, Alessandra Tucci, Silvia Franceschetti, Andrea Evangelista, Valentina Lenti, Renato Fanin, Alessandro Levis

Blood (2014) 124 (21): 1755.

https://doi.org/10.1182/blood.V124.21.1755.1755

Published: 2014

Journal Articles

Molecular Lesions Of Signalling Pathway Genes In Indolent B-Cell Lymphoproliferations Mimicking Splenic Marginal Zone Lymphoma

Davide Rossi, Alessio Bruscaggin, Sara Monti, Stefania Cresta, Rosella Famà, Luca Arcaini, Silvia Franceschetti, Marco Lucioni, Fabrizio Tabbò, Enrico Tiacci, Giorgio Inghirami, Marco Paulli, Brunangelo Falini, Robin Foà, Gianluca Gaidano

Blood (2013) 122 (21): 4250.

https://doi.org/10.1182/blood.V122.21.4250.4250

Published: 2013

Journal Articles

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Blood (2013) 122 (21): 850.

https://doi.org/10.1182/blood.V122.21.850.850

Published: 2013

Journal Articles

Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi

Francesco Zaja, Flavia Salvi, MD, Silvia Franceschetti, Gianluca Gaidano, Marco Ladetto, Manuela Zanni, Gian Matteo Pica, Angelo Michele Carella, Annalisa Chiappella, Stefano Volpetti, Pier Luigi Zinzani, Alfonso Maria D'Arco, Andrea Evangelista, Alessandra Tucci, Pier Paolo Piccaluga, MD, PhD, Stefano A. Pileri, Renato Fanin, MD, Alessandro Levis

Blood (2013) 122 (21): 3047.

https://doi.org/10.1182/blood.V122.21.3047.3047

Published: 2013

Journal Articles

Histologic Transformation in Marginal Zone Lymphomas

Silvia Franceschetti, MD, Annarita Conconi, MD, Kathrin Aprile Von Hohenstaufen, MD, Gloria Margiotta Casaluci, MD, Anastasios Stathis, MD, Alden Moccia, MD, Michele Ghielmini, MD, Francesco Bertoni, MD, Gianluca Gaidano, MD, PhD, Franco Cavalli, MD, Emanuele Zucca, MD

Blood (2012) 120 (21): 1571.

https://doi.org/10.1182/blood.V120.21.1571.1571

Published: 2012

Journal Articles

R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL)

Blood (2012) 120 (21): 1615.

https://doi.org/10.1182/blood.V120.21.1615.1615

Published: 2012

Journal Articles

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 903.

https://doi.org/10.1182/blood.V120.21.903.903

Published: 2012

Journal Articles

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Blood (2012) 120 (21): 2720.

https://doi.org/10.1182/blood.V120.21.2720.2720

Published: 2012

Journal Articles

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

Blood (2012) 120 (16): 3222–3228.

https://doi.org/10.1182/blood-2012-04-423095

Published: 2012

Journal Articles

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Patrizia Pregno, Annalisa Chiappella, Marilena Bellò, Barbara Botto, Simone Ferrero, Silvia Franceschetti, Francesca Giunta, Marco Ladetto, Giorgio Limerutti, Massimo Menga, Maura Nicolosi, Giorgio Priolo, Benedetta Puccini, Luigi Rigacci, Flavia Salvi, Luca Vaggelli, Roberto Passera, Gianni Bisi, Umberto Vitolo

Blood (2012) 119 (9): 2066–2073.

https://doi.org/10.1182/blood-2011-06-359943

Published: 2012

Journal Articles

Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers

Annarita Conconi, MD, Silvia Franceschetti, MD, Chiara Lobetti-Bodoni, MD, Anastasios Stathis, MD, Riccardo Bruna, MD, Paola Riccomagno, MD, Francesco Bertoni, MD, Michele Ghielmini, MD, Franco Cavalli, MD, Gianluca Gaidano, Emanuele Zucca, MD

Blood (2011) 118 (21): 2660.

https://doi.org/10.1182/blood.V118.21.2660.2660

Published: 2011

Journal Articles

Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi

Blood (2011) 118 (21): 2636.

https://doi.org/10.1182/blood.V118.21.2636.2636

Published: 2011

Journal Articles

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

Chiara Lobetti-Bodoni, MD, Paola MV Rancoita, PhD, Silvia Montoto, MD, Armando Lopez-Guillermo, MD, Annarita Conconi, MD, Rita Coutinho, MD, Janet Matthews, Silvia Franceschetti, MD, Francesco Bertoni, MD, Franco Cavalli, MD, Michele Ghielmini, MD, Andrew Lister, MD, Emili Montserrat, MD, Emanuele Zucca, MD

Blood (2011) 118 (21): 1593.

https://doi.org/10.1182/blood.V118.21.1593.1593

Published: 2011

Journal Articles

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Blood (2011) 117 (8): 2405–2413.

https://doi.org/10.1182/blood-2010-07-296244

Published: 2011

Includes: Supplemental data

Journal Articles

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

Blood (2011) 117 (5): 1595–1604.

https://doi.org/10.1182/blood-2010-01-264275

Published: 2011

Includes: Supplemental data

Journal Articles

Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL)

Annalisa Chiappella, Patrizia Pregno, Pier Luigi Zinzani, Andrea Evangelista, Alberto Fabbri, Fabio Facchetti, Andres JM Ferreri, Silvia Franceschetti, Roberto Freilone, Livio Gargantini, Daniela Gioia, Anna Marina Liberati, Maura Nicolosi, Lorella Orsucci, Luigi Rigacci, Eleonora Russo, Vittorio Stefoni, Alessandra Tucci, Umberto Vitolo

Blood (2010) 116 (21): 3965.

https://doi.org/10.1182/blood.V116.21.3965.3965

Published: 2010

Journal Articles

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

Blood (2010) 116 (21): 992.

https://doi.org/10.1182/blood.V116.21.992.992

Published: 2010

NARROW

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenstrom's Macroglobulinemia

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Molecular Lesions Of Signalling Pathway Genes In Indolent B-Cell Lymphoproliferations Mimicking Splenic Marginal Zone Lymphoma

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi

Histologic Transformation in Marginal Zone Lymphomas

R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL)

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers

Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL)

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only